Diabeloop touts 12-week, real-world study of closed-loop system
Diabeloop reported this week that people with Type I diabetes who used its DBLG1 closed-loop insulin delivery system in an at-home setting spent a greater percentage of time in the target blood glucose range, with fewer hypoglycemic events, compared to those who use an open-loop system.
The 12-week study, which enrolled 68 adults with Type I diabetes, randomly assigned participants to two groups – 33 people used the DBLG1 system and 35 people used their usual pump and glucose sensor.
According to Diabeloop, people using the DBLG1 system spent 69.3% of the time in the target blood glucose range of 70-180 mg/dl compared to 56.6% of people using an open-loop system. People in the DBLG1 group spent 2% of the time in hypoglycemia, compared to 4.5% for the open-loop group.
“The DBLG1 is a powerful and customizable algorithm system for Type I diabetes treatment that may enable patients to significantly and durably reduce their glucose levels without an increase in hypoglycemic events,” lead author Dr. Sylvia Franc said in prepared remarks. “The results of our study confirm in real life, over a 12-week period, the positive results previously observed in an inpatient setting.”
Were you at this year’s ADA meeting? Drop me a note in the comments – what major themes emerged for you?